Sign In
Buy JNJ
$241.00
+1.92 (+0.80%)
At Close: Jun 24, 2026
Forget About a Market Correction: Baby Boomers Should Buy These 3 Bulletproof Dividend Stocks Now
03:49pm, Wednesday, 12'th Mar 2025
Market volatility can be unsettling for any investor.
Lilly, J&J boosted spending on executive security after UnitedHealth shooting
01:16pm, Wednesday, 12'th Mar 2025
U.S. drugmakers Johnson & Johnson and Eli Lilly increased spending on security for their top executives in 2024, with both citing increased threats after a UnitedHealth insurance executive was murdere
Six Dean Omar Branham Shirley Attorneys Honored for Representation of Plaintiffs
12:58pm, Wednesday, 12'th Mar 2025
DALLAS--(BUSINESS WIRE)--Leading plaintiff trial firm Dean Omar Branham Shirley, LLP is pleased to announce the selection of partners Jessica Dean, Amin Omar, Trey Branham, Lisa Shirley, Ben Braly and
ChatGPT picks 3 safe haven stocks to buy for 2025
12:16pm, Wednesday, 12'th Mar 2025
The advent of artificial intelligence (AI) and machine learning has, in many ways, revolutionized the financial markets.
Cramer's Mad Dash: Johnson & Johnson
10:38am, Tuesday, 11'th Mar 2025
Jim Cramer breaks down why he's keeping an eye on shares of Johnson & Johnson.
3 Dividend Stocks Set to Provide Stability in Market Chaos
01:20pm, Monday, 10'th Mar 2025
Investors were in growth mode in the last two years as the stock market delivered blockbuster returns.
Topline results also show investigational targeted oral peptide icotrokinra achieved clinical remission rates up to 30.2% at Week 12 and a favorable safety profile in Phase 2b ANTHEM-UC study Clini
Icotrokinra results show potential to set a new standard of treatment in plaque psoriasis
09:00am, Saturday, 08'th Mar 2025
Standout combination of complete skin clearance and favorable safety profile in a once daily pill could shift treatment paradigm Nearly half of patients with moderate-to-severe plaque psoriasis (PsO)
JNJ Halts Development of Depression Drug Over Efficacy Concerns
01:45pm, Friday, 07'th Mar 2025
While J&J is yet to give up on aticaprant, it decides to stop developing the drug for major depressive disorder due to a lack of sufficient efficacy.
3 Dividend Kings Shaking Off Market Woes
12:15pm, Friday, 07'th Mar 2025
While the market throws its tariff tantrum, several long-established companies with years of operational success have seen their shares move higher, displaying relative strength.
Pfizer Vs. Johnson & Johnson: Who's The Better Bargain For Investors
09:34am, Friday, 07'th Mar 2025
Johnson & Johnson and Pfizer occupy leading positions in the healthcare sector. Each of them has advantages, as well as dark spots in the portfolio of drugs relative to the comparator. In this article
Stock Market Drama Highlights Trump's Game Of Chicken With Economy
08:00am, Friday, 07'th Mar 2025
Uncertainty socked the U.S. stock market in February, short-circuiting an early-year rally and saddling fund investors with losses. The post Stock Market Drama Highlights Trump's Game Of Chicken With
J&J to stop late-stage study of add-on depression drug
05:28pm, Thursday, 06'th Mar 2025
Johnson & Johnson said on Thursday it will discontinue a late-stage study of its add-on treatment for major depressive disorder due to insufficient efficacy in the target patient population.
10 Dividend Aristocrat Bargains To Help You SWAN During This Trade War Turmoil
07:00am, Thursday, 06'th Mar 2025
The trade war is causing market volatility, with stocks falling and bonds performing well as investors seek hedges against economic slowdown fears. Dividend aristocrats, particularly low-volatility, d
2 Dow Stocks to Buy Hand Over Fist in March and 1 to Avoid
04:06am, Thursday, 06'th Mar 2025
For nearly 129 years, the iconic Dow Jones Industrial Average (^DJI 1.14%) has served as a key barometer of Wall Street's health and stability. This index, which began its existence with a dozen mostl
